INSIGHTS ON CONTRACT PHARMA MANUFACTURING

• Supporting Complex Manufacturing For Liquid And Lyophilized Drug Products

  Aseptic fill and finish operations gain efficiency and precision with modular isolator technology, inline weight checks, and lyophilization, which are ideal for mRNA-LNPs and other sensitive modalities.

• How In-House CDMO Analytics Reduce Risk and Cost

  Integrated analytical capabilities within a CDMO are increasingly preferred to overcome challenges associated with outsourcing analysis in biopharma development and manufacturing.

• Collaboration An Untapped Fuel For Driving Biopharma R&D

  Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.

• Development And Manufacture Of A Highly Potent OSD Product

  Highly potent drug compounds require advanced containment and robust technical transfer protocols. CDMOs overcome challenges through meticulous testing, specialized tooling, and strong supplier relationships.

• TPDs: Developing The Next Generation Of Oral Therapeutics

  Targeted Protein Degraders are a revolutionary drug class with challenges in bioavailability and formulation complexity. Strategic CDMO partnerships are key to successful, scalable development.

• Breaking Barriers: Enhancing The Bioavailability Of Orally Delivered TPDs

  The large, bulky structure of TPDs limits solubility and permeability. Enabling technologies like spray drying, hot melt extrusion, and nanomilling are key to formulating these challenging molecules.

• How Global Supply Chain Centers Amplify CGT Program Growth

  Consolidating logistics, cryopreservation, and storage eliminates handoffs and risk. This single-platform approach creates the consistency needed for global compliance and growth.

• Hidden Risks In Your Supply Chain: Regulatory Support Can Save Your CGT

  Unvalidated shipping lanes and incomplete documentation can cause regulatory delays. Proactive qualification and risk assessments are vital for compliance and safeguarding product integrity.

• What's Next For ATMP Regulation In EMEA

  Fragmented national regulations for pricing, customs, and reimbursement demand tailored supply chain strategies. Adapting to country-specific hurdles is essential for product integrity and patient access.

• Contamination Control Strategies: Comparing Cleanrooms, RABS, Isolators

  Sterile manufacturing relies on three main contamination control strategies (CCSs): cleanrooms, RABS, and isolators. Understand how each system compares in sterility assurance, startup cost, and operational flexibility.